Avita Medical to Present at SoCalBio Investor Conference &

Avita Medical to Present at SoCalBio Investor Conference & Exhibition 
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) --
11/05/12 --  Regenerative medicine company Avita Medical Ltd. (ASX:
AVH) (OTCQX: AVMXY) today announced that it will be presenting at the
upcoming SoCalBio Investor Conference & Exhibition. The event will
take place on November 7, 2012 at the Omni Hotel in Los Angeles,
California. 
The Company will be presenting in the Wound Healing & Regenerative
Medicine Group. 
"We are pleased to be presenting at this quality bioscience industry
conference," said Dr. William Dolphin, Avita Medical's CEO.
"ReCell(R) Spray-On Skin(TM) is on the market in other countries and
undergoing FDA clinical trials in the US. This conference is a great
venue to generate awareness among the US investment community as we
approach FDA submission." 
This is a one-day conference organized annually by the Southern
California Biomedical Council (SoCalBio) to showcase the strength and
future of the bioscience industry in Los Angeles/Orange County and
neighboring communities. For more information on the conference:
http://www.socalbio.org/SocalBio_2012/home_2012.htm 
ABOUT AVITA MEDICAL LTD.
 Avita Medical
(http://www.avitamedical.com/) develops and distributes regenerative
and tissue-engineered products for the treatment of a broad range of
wounds, scars and skin defects. Avita's patented and proprietary
tissue-culture, collection and application technology provides
innovative treatment solutions derived from a patient's own skin. The
company's lead product, ReCell(R) Spray-On Skin(TM), is used in a
wide variety of burns, plastic, reconstructive and cosmetic
procedures. ReCell is patented, CE-marked for Europe, TGA-registered
in Australia, and SFDA-cleared in China. ReCell is on market and
generating early revenues. ReCell is not available for sale in the
United States; in the US ReCell is an investigational device limited
by federal law to investigational use. A Phase III FDA trial is in
process.  
Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:+1 838-352-9400
Email: ssung@avitamedical.com 
Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email: jramson@proactivecapitalgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.